NCT03356080 is a Phase 2 clinical trial of Decitabine in Acute Myeloid Leukemia, sponsored by Shanghai Tong Ren Hospital.

Who is sponsoring NCT03356080?

NCT03356080 is sponsored by Shanghai Tong Ren Hospital.

What drugs are being tested in NCT03356080?

Interventions in NCT03356080: Decitabine, Cytarabine, All-transretinoic acid, G-CSF.

What condition does NCT03356080 study?

NCT03356080 studies Acute Myeloid Leukemia, Myelodysplastic Syndrome.

Is NCT03356080 still recruiting?

NCT03356080 is currently status unknown. Last updated 29 November 2017.

Last reviewed 2017-11-29 · How we verify

NCT03356080

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess

Status unknown Phase 2 Last updated 29 November 2017

What this trial tests

Phase 2 trial testing Decitabine in Acute Myeloid Leukemia in 50 participants. Status unknown.

Timeline

7 July 2017

Primary endpoint
7 July 2019

7 July 2020

Quick facts

Lead sponsor	Shanghai Tong Ren Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	7 July 2017
Primary completion	7 July 2019
Estimated completion	7 July 2020
Sites	6 locations across China

Drugs / interventions tested

Decitabine (decitabine) — full drug profile →
Cytarabine — full drug profile →
All-transretinoic acid — full drug profile →
G-CSF (g-csf) — full drug profile →

Conditions studied

Acute Myeloid Leukemia — all drugs for Acute Myeloid Leukemia →
Myelodysplastic Syndrome — all drugs for Myelodysplastic Syndrome →

Sponsor

Shanghai Tong Ren Hospital

Who can join

Adults 18 to 90, any sex, with Acute Myeloid Leukemia or Myelodysplastic Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate of the clinical efficacy and safety of DLAAG protocol in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome with blast excess

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Advances and challenges in retinoid delivery systems in regenerative and therapeutic medicine.
Ferreira R, Napoli J, Enver T, Bernardino L, et al · · 2020 · cited 81× · PMID 32848154 · DOI 10.1038/s41467-020-18042-2
Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Wong KK, Hassan R, Yaacob NS. · · 2021 · cited 38× · PMID 33718188 · DOI 10.3389/fonc.2021.624742
All-trans retinoic acid in hematologic disorders: not just acute promyelocytic leukemia.
Chen Y, Tong X, Lu R, Zhang Z, et al · · 2024 · cited 16× · PMID 39027338 · DOI 10.3389/fphar.2024.1404092
The AML immune paradox: decoding escape pathways and pioneering checkpoint, vaccine, and combination strategies.
Soleimani Samarkhazan H, Shafiei FS, Taghinejad Z, Maleknia M, et al · · 2025 · cited 14× · PMID 40634759 · DOI 10.1007/s10238-025-01795-9
Historical expectations with DNA methyltransferase inhibitor monotherapy in MDS: when is combination therapy truly "promising"?
Brunner AM, Fell G, Steensma DP. · · 2022 · cited 3× · PMID 35143613 · DOI 10.1182/bloodadvances.2021006357

Verify or expand the search:

Other trials of Decitabine

Trials testing the same drug.

NCT07012044 — A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After · Phase 1 · not yet recruiting
NCT07511062 — Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML · Phase 1 · not yet recruiting
NCT07389239 — A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies. · Phase 1, PHASE2 · not yet recruiting
NCT07177079 — High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML · Phase 1 · recruiting
NCT07148947 — Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant · Phase 2 · recruiting

Other recruiting trials for Acute Myeloid Leukemia

Currently open trials in the same condition.

NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
NCT06782542 — Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for I · Phase 2 · recruiting
NCT07177079 — High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML · Phase 1 · recruiting
NCT07384715 — First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelod · Phase 1 · recruiting
NCT07107126 — Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes · Phase 1 · recruiting

Other Shanghai Tong Ren Hospital trials

Trials by the same sponsor.

NCT06583564 — The Prognosis Effect of Indocyanine Green (ICG) Fluorescence Guided Surgery on Disease-free Survival (DFS) of Stage III · NA · not yet recruiting
NCT06508541 — The Prognosis of Colorectal Cancer Patients After Indocyanine Green Fluorescence-guided Radical Surgery · completed
NCT05736978 — Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results · Phase 2 · recruiting
NCT05736965 — A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With A · Phase 2 · recruiting
NCT05526300 — Intelligent Hypertension Intervention Study · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03356080 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Tong Ren Hospital
Last refreshed: 29 November 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03356080.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing